Discover why Eli Lilly and Company's retatrutide weight loss breakthrough positions LLY as a leader in obesity therapeutics.

The maker of Zepbound reported results from a study of retatrutide, which targets three hormones in the body and led to much more weight loss than any approved drug.

Eli Lilly leads incretins via Zepbound/Mounjaro, retatrutide at 28.7% loss, $50B R&D and US buildout, 2025 guidance, ...

Step aside, semaglutide—retatrutide is showing the most impressive weight loss results of any obesity drug to date.

LLY's retatrutide posts strong weight-loss and pain-reduction results in its first Phase III study, boosting investor ...

Eli Lilly said its next generation weight-loss drug retatrutide resulted in significant weight loss and reduced knee pain in ...

Eli Lilly's experimental drug, retatrutide, showed strong results in a late-stage trial, helping patients lose nearly 29% of ...

In the TRIUMPH-4 trial, participants with obesity and knee osteoarthritis taking the highest dose of retatrutide (12 mg) lost ...

Eli Lilly’s experimental weight-loss drug retatrutide led to an average weight reduction of up to 28.7%—more than 71 ...

In an added benefit, more than one in eight people taking the highest dose of Retratrutide were completely free of arthritic ...

Retatrutide, the next generation of GLP-1 drug from Eli Lilly, helped participants lose an average of 71.2 pounds and reduce ...

Eli Lilly said on Thursday its next-generation obesity drug helped patients lose an average of 28.7% of their weight in a ...